Company Shares of Ocular Therapeutix (NASDAQ:OCUL) Rally 21.22%

Ocular Therapeutix (NASDAQ:OCUL) has been under a strong bear grip, hence the stock is down -7.06% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 19.69% in the past 1 week. The stock has risen by 21.22% in the past week indicating that the buyers are active at lower levels, but the stock is down -5.56% in the past 4 weeks.

The company shares have dropped -71.86% from its 1 Year high price. On Jul 20, 2015, the shares registered one year high at $29.22 and the one year low was seen on Jun 27, 2016. The 50-Day Moving Average price is $7.42 and the 200 Day Moving Average price is recorded at $8.69.

The stock has recorded a 20-day Moving Average of 9.03% and the 50-Day Moving Average is 31.66%.


Ocular Therapeutix (NASDAQ:OCUL): stock turned positive on Friday. Though the stock opened at $5.38, the bulls momentum made the stock top out at $6.11 level for the day. The stock recorded a low of $5.31 and closed the trading day at $5.94, in the green by 11.24%. The total traded volume for the day was 875,374. The stock had closed at $5.34 in the previous days trading.

In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the CEO of Ocular Therapeutix, Inc, Sawhney Amarpreet, had purchased 10,000 shares in a transaction dated on June 9, 2016. The transaction was executed at $6.7 per share with total amount equaling $67,000.

Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Companys bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. Its hydrogel is a bioresorbable formulation of polyethylene glycol (PEG), which when constituted with water takes on a gelatinous consistency. The Companys product pipeline includes marketed candidate ReSure Sealant and products under development, such as OTX-DP, OTX-TP, OTX-MP and anti-VEGF hydrogel depot. The Companys lead product candidates are OTX-DP and OTX-TP.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.